Berliner Nanotechnology Company Doubles Turnover

Alexander Hermann, chief financial officer, states: “We are pleased to have surpassed the goals we aspired to, for this generates a high degree of confidence in the company’s growth forecasts among all involved: customers, staff and investors. In the coming months the result will be impaired by high advance costs in the R & D area, especially due to scheduled pre-clinical experiments. However, the successful conclusion of these tests promises a considerable increase in turnover in the next fiscal year, as a large number of potential pharmaceutical customers hold them to be an important milestone for expanding and intensifying business relations with Capsulution.”

Capsulution NanoScience AG is a leading nanotechnology company focusing on the development of tailor-made drug delivery systems and other innovative life science products based on tunable nano-sized capsules. The company applies its worldwide-patented so-called LBL-Technology®. Based on their minute size, their functionality and their highly reproducible production process the tunable capsules can be used for a multitude of different applications. Accordingly, the precisely sized capsules can be made to function in a manner to suit the intended application, and can be given the appropriate biochemical, electrical, optical and magnetic properties as required by the customer. In order to meet customers needs for complete product solutions Capsulution has recently designated EBARA Corp. as the preferred developer, manufacturer and distributor for automated LBL-units. Only six month after the signing of the licence agreement, EBARA has started operation of the first prototype plant (LBL-Unit®) for the manufacture of Capsulution's LBL capsules. In 2005, renowned growth consultants Frost & Sullivan have awarded the year’s “Product Differentiation Innovation Award” in the global nanobiotechnology market to Capsulution NanoScience AG, Berlin. The company has received the award for the innovative and diverse use of their proprietary nanobiotechnology product platform, which can be implemented in various life sciences applications.

Source: Verivox